Hadasit completes preclinical testing of Double Lumen PCI guiding catheter
Hadasit, the technology transfer company of Hadassah Medical Organization, has completed its preclinical testing of a prototype of the Double Lumen PCI guiding catheter for use in the treatment of coronary artery disease.
The Double Lumen PCI guiding catheter has two lumens rather than one. The second lumen allows for a continuous medication infusion to the coronary artery during PCI, according to the Ein Kerem, Israel-based Hadasit.
“There are currently only two options by which to give necessary medications, such as antiplatelets or anticoagulants, to a patient during a coronary artery procedure. The first is by IV; the second is by interrupting the procedure and giving injections through a conventional one lumen catheter. With the introduction of the Double Lumen PCI guiding catheter, medications can now be delivered directly to the coronary artery without interrupting the procedure and without needing to wait for it to arrive through the blood stream from the IV,” said David Rott, MD, a cardiologist at the Hadassah Medical Center in Jerusalem.
The Double Lumen PCI guiding catheter has two lumens rather than one. The second lumen allows for a continuous medication infusion to the coronary artery during PCI, according to the Ein Kerem, Israel-based Hadasit.
“There are currently only two options by which to give necessary medications, such as antiplatelets or anticoagulants, to a patient during a coronary artery procedure. The first is by IV; the second is by interrupting the procedure and giving injections through a conventional one lumen catheter. With the introduction of the Double Lumen PCI guiding catheter, medications can now be delivered directly to the coronary artery without interrupting the procedure and without needing to wait for it to arrive through the blood stream from the IV,” said David Rott, MD, a cardiologist at the Hadassah Medical Center in Jerusalem.